Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLDN18.2-307-ADC
- Development stage
- Unknown
- Lead developer
- TORL BioTherapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CLDN18.2-307-ADC (also known as TORL-2-307-ADC) is an investigational antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), a tight junction protein that is aberrantly expressed in several solid tumors, particularly gastric, gastroesophageal junction, and pancreatic cancers. Developed by TORL BioTherapeutics in collaboration with the Slamon Research Lab at the University of California, Los Angeles (UCLA), the drug consists of a humanized monoclonal antibody (CLDN18.2-307-mAb) conjugated to the microtubule-disrupting cytotoxic payload monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon binding to CLDN18.2 on the surface of tumor cells, the ADC is internalized and trafficked to the lysosomal compartment, where MMAE is released to inhibit tubulin polymerization, leading to G2/M cell cycle arrest and apoptosis. CLDN18.2-307-ADC is currently being evaluated in Phase I clinical trials for patients with advanced CLDN18.2-positive solid tumors.
- Other names
- anti-CLDN18.2 ADC TORL-2-307-ADCanti-CLDN-18.2 ADC TORL-2-307-ADCanti-CLDN 18.2 ADC TORL-2-307-ADCanti-CLDN18.2/MMAE ADC TORL-2-307-ADC
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on CLDN18.2-307-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLDN18.2-307-ADC.